| Market Cap | 12.41M | P/E | - | EPS this Y | 3.60% | Ern Qtrly Grth | - |
| Income | -3.16M | Forward P/E | -20.09 | EPS next Y | 100.00% | 50D Avg Chg | -7.00% |
| Sales | 4.09M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 32.00% |
| Dividend | N/A | Price/Book | 1.81 | EPS next 5Y | - | 52W High Chg | -28.00% |
| Recommedations | 2.00 | Quick Ratio | 1.31 | Shares Outstanding | 6.23M | 52W Low Chg | 103.00% |
| Insider Own | 23.64% | ROA | -21.40% | Shares Float | 4.93M | Beta | 0.80 |
| Inst Own | 2.23% | ROE | -49.80% | Shares Shorted/Prior | 17.57K/24.05K | Price | 2.21 |
| Gross Margin | 15.14% | Profit Margin | -77.21% | Avg. Volume | 82,653 | Target Price | 6.00 |
| Oper. Margin | -142.51% | Earnings Date | - | Volume | 23,591 | Change | -6.36% |
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments, Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications under the MedaGel brand; and beauty and cosmetic solutions, such as wrinkle and skin cream applications under the LumaGel Beauty brand name. It is also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
| Maxim Group | Buy | Feb 25, 22 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Stein John Nachum | Director Director | Sep 26 | Buy | 1.96 | 2,500 | 4,900 | 500,019 | 09/28/23 |
| Henry Scott Robert | Director Director | Sep 12 | Buy | 2.27 | 10,500 | 23,835 | 112,038 | 09/14/23 |
| Henry Scott Robert | Director Director | Aug 21 | Buy | 1.94 | 2,980 | 5,781 | 101,538 | 08/23/23 |
| Henry Scott Robert | Director Director | Jun 08 | Buy | 2.244 | 3,558 | 7,984 | 98,558 | 06/12/23 |
| Stein John Nachum | Director Director | Jun 07 | Buy | 2.49 | 10,000 | 24,900 | 497,458 | 06/09/23 |
| STEFANSKY DAVID | Director Director | Jun 07 | Buy | 2.36 | 3,000 | 7,080 | 50,091 | 06/09/23 |
| Henry Scott Robert | Director Director | May 31 | Buy | 2.33 | 3,000 | 6,990 | 95,000 | 06/02/23 |
| STEFANSKY DAVID | Director Director | May 30 | Buy | 2.48 | 7,000 | 17,360 | 47,091 | 06/01/23 |
| glassman steven mark | Director Director | May 30 | Buy | 2.38 | 4,200 | 9,996 | 119,292 | 06/01/23 |
| ZELDIS JEROME B | Director Director | May 26 | Buy | 2.3377 | 5,000 | 11,688 | 93,028 | 05/30/23 |
| Henry Scott Robert | Director Director | May 22 | Buy | 1.95 | 7,000 | 13,650 | 92,000 | 05/24/23 |
| STEIN NACHUM | Director Director | Nov 21 | Buy | 1.19 | 7,100 | 8,449 | 487,458 | 12/02/22 |
| STEFANSKY DAVID | Director Director | Aug 30 | Buy | 1.6560 | 5,000 | 8,280 | 27,591 | 08/31/22 |
| Spinrad Yaakov | Director Director | Aug 30 | Buy | 1.68 | 1,648 | 2,769 | 1,648 | 08/31/22 |
| STEFANSKY DAVID | Director Director | Aug 25 | Buy | 1.73 | 5,000 | 8,650 | 22,591 | 08/26/22 |
| STEFANSKY DAVID | Director Director | Aug 15 | Buy | 1.85 | 5,372 | 9,938 | 17,591 | 08/17/22 |
| STEFANSKY DAVID | Director Director | Jun 24 | Buy | 1.5962 | 3,128 | 4,993 | 12,219 | 06/27/22 |